Current Report Filing (8-k)
October 01 2020 - 9:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported):
September 29, 2020
Adial Pharmaceuticals, Inc.
(Exact name of registrant as specified
in charter)
Delaware
(State or other jurisdiction of incorporation)
001-38323
|
|
82-3074668
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
1180 Seminole Trail, Suite 495
Charlottesville, Virginia 22901
(Address of principal executive offices
and zip code)
(434) 422-9800
(Registrant’s telephone number
including area code)
(Former Name and Former Address)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbols
|
|
Name of each exchange on which registered
|
Common Stock
|
|
ADIL
|
|
NASDAQ
|
|
|
|
|
|
Warrants
|
|
ADILW
|
|
NASDAQ
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
On September 29,
2020, Adial Pharmaceuticals, Inc., a Delaware corporation (the “Company”),
received notice of exercise of previously issued warrants to purchase a total of 225,000 shares (the “Shares”) of
the Company’s common stock, par value $0.001, for aggregate proceeds of $450,000. The funds were subsequently received
and the Shares were issued effective the same date.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: October 1, 2020
|
ADIAL PHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
/s/ William B. Stilley, III
|
|
Name:
|
William B. Stilley
|
|
Title:
|
President and Chief Executive Officer
|
2
Adial Pharmaceuticals (NASDAQ:ADIL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adial Pharmaceuticals (NASDAQ:ADIL)
Historical Stock Chart
From Sep 2023 to Sep 2024